Compare Dyne Therapeutics Inc. Common Stock (DYN) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.95B). The key difference: VanEck JP Morgan EM Local Currency Bond ETF is the larger of the two by market cap, and VanEck JP Morgan EM Local Currency Bond ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and VanEck JP Morgan EM Local Currency Bond ETF for 40 Days on average.
| DYN | EMLC | |
|---|---|---|
Market Cap | $2.86B | $4.95B |
Volume | 3,341,579 | 2,930,860 |
Sector | Health | Fixed Income |
52-Week High | $26.78 | $26.59 |
52-Week Low | $14.60 | $24.53 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
EMLC trades at $24.92, up 0.24% on the day, but technical indicators signal a bearish trend with the stock recently hitting a 52-week low. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though some analysts see value in emerging market local currency bonds. Recent dividends of $0.14 and $0.13 were declared for October and August 2026.
Outlook remains cautious as dollar strength pressures emerging market currencies, though diversification benefits and yield potential offer long-term opportunities. Key risks include currency volatility and rising global bond yields, while institutional sentiment appears mixed with technical weakness dominating near-term price action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
